The what, why and how of Bayesian clinical trials monitoring.

We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5-Fluorouracil for colorectal cancer.

[1]  K. K. Lan,et al.  Stochastically curtailed tests in long–term clinical trials , 1982 .

[2]  Christopher Jennison,et al.  Interim analyses: the repeated confidence interval approach , 1989 .

[3]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[4]  T R Fleming,et al.  Approaches to monitoring clinical trials. , 1989, Journal of the National Cancer Institute.

[5]  Anastasios A. Tsiatis,et al.  Exact confidence intervals following a group sequential trial: A comparison of methods , 1988 .

[6]  N L Geller,et al.  Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. , 1987, Biometrics.

[7]  P. Macaskill,et al.  Stopping rules for clinical trials incorporating clinical opinion. , 1984, Biometrics.

[8]  S J Pocock,et al.  Interim analyses for randomized clinical trials: the group sequential approach. , 1982, Biometrics.

[9]  D. Spiegelhalter,et al.  Monitoring clinical trials: conditional or predictive power? , 1986, Controlled clinical trials.

[10]  T. Fleming,et al.  Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[12]  D J Spiegelhalter,et al.  Comparison of Bayesian with group sequential methods for monitoring clinical trials. , 1989, Controlled clinical trials.